NEXUS AG __ Financial Highlights for the Fiscal Year 2021
2021 | 2020 | Change | |
Sales, operating result and cash flow | KEUR | KEUR | (in %) |
Sales | 188,178 | 162,944 | 15.5 |
Segment revenues Healthcare Software (unconsolidated) | 181,202 | 154,613 | 17.2 |
Segment revenues Healthcare Service (unconsolidated) | 12,937 | 15,279 | -15.3 |
Domestic sales | 103,044 | 88,611 | 16.3 |
Sales in foreign countries | 85,134 | 74,333 | 14.5 |
EBITDA | 40,770 | 36,640 | 11.3 |
EBITA | 28,872 | 24,284 | 18.9 |
EBIT | 24,114 | 19,915 | 21.1 |
EBT | 23,055 | 19,592 | 17.7 |
Consolidated net income | 17,459 | 15,091 | 15.7 |
Cash flow from operating activities | 31,386 | 30,947 | 1.4 |
Cash flow from investment activities | -21,249 | -22,005 | -3.4 |
Earnings per share (undiluted / diluted) in EUR | 1.09 | 0.95 | 14.7 |
Ongoing development costs and depreciations | |||
Capitalization of software developments | 2,531 | 3,013 | -16.0 |
Development costs | 34,633 | 27,592 | 25.5 |
Total depreciation | 16,656 | 16,725 | -0.4 |
Depreciation from purchase price allocation | 4,758 | 4,369 | 8.9 |
Assets and equity capital | |||
Non-current assets | 181,118 | 159,021 | 13.9 |
Current assets | 66,223 | 64,141 | 3.2 |
Liquid assets | 26,172 | 26,449 | -1.0 |
Equity capital | 142,403 | 123,583 | 15.2 |
Share price (closing price, Xetra, in EUR) | 71.60 | 51.00 | 40.4 |
Employees (annual average) | 1,469 | 1,322 | 11.1 |
As rounded figures are used in this report, it is possible that the totals and calculated percentage figures may vary slightly.
1 Nexus AG / Annual Report 2021 - Financial-Highlights
Content __ Annual Report 2021
03 | 30 | ||||
Letter to our Shareholders | Economic | ||||
Key figures | |||||
08 | 35 | ||||
Report of the Supervisory Board | Consolidated financial Statement |
1142
Our Software | Notes to the Consolidated Financial |
Statements of 2021 |
1492
Investor Relations | Statement from the Legal |
Representatives |
1593
Our NEXUS Management Team | Audit Certificate of the |
Independent Auditor |
20
Group Management Report 2021
2
01 __ Letter to our Shareholders
Dear Shareholders:
Coping with the pandemic is not only a health and social challenge; It is undoubtedly also an entrepreneurial feat. The rapidly changing conditions and regulations have continuously challenged our organization, our employees and our service provision in 2021. More than ever, it was important to find flexible solutions for increasingly new problems and rules in the short term.
Especially in this phase, it was important that our customers - hospitals, rehabilitation facilities, homes and doctors - were supported with first- class service and tailor-made software offers. They deserve our thanks and hard work for the great commitment that the employees of these institutions are making in the pandemic.
We are therefore also proud that we have been able to work hard and at the same time have been able to conclude 2021 very successfully both economically and in terms of content. With confidence, innovation and flexibility, we were able to achieve all the goals of the year and maintain our long-term prospects for success.
__ Dr. Ingo Behrendt, Chief Executive Officer (CEO)
It is thanks to our dedicated customers and employees that 2021 was such a successful year for our company. The digitalization of healthcare facilities is a demanding and collaborative task that always succeeds when providers and customers work together in a committed manner.
But we also had to fight in 2021. Stricter curfews, travel and contact bans in some countries and regions temporarily led to declining demand or project delays.
The elimination of trade fairs and personal encounters has limited our marketing activities and the confusing situation in the fight against pandemics has led to delays or cancellations of IT projects in many hospitals.
__ 2021: Pandemic and Digitization, a Challenging Year
Overall, healthcare institutions have faced numerous shifts in priorities. Many work processes have become more digital, and the necessity and advantages of digitization are becoming increasingly clear. Digitization has also become a major trend in the healthcare sector. This can be seen in the numerous state-sponsored digitization programs that were launched in Germany, France, the Netherlands and other countries within a short time. Very extensive programs were launched in this area and provided with considerable resources. The reason is not least the recognition that the pandemic is also a crisis of medical data management and medical statistics and that improved digital infrastructure is one attempt at a solution.
__ 2021: Focus on Innovation as a Success Factor
It must not be overlooked that the path to a digitalization of the healthcare system is conceptually still in motion. Different product and technology concepts compete with each other and there is still no uniform view of the content and technological structure of digitization on the market. While monolithic system solutions for healthcare facilities have been preferred in many countries, the strategy of modular, interoperable systems implemented by NEXUS is currently gaining ground. Many countries are working on the development of an interoperable ecosystem in health IT and are focusing heavily on innovation. With our modular, platform- oriented system, we are very well positioned for this trend and meet the expectations of our customers with our focus on innovation. Innovations that provide users with immediate work facilitation and a positive user experience (UX) are particularly in demand:
2010 to 2021 __ Group Sales in EUR million
200 | ||||||||||||||||||||||||||||||||||||||
180 | ||||||||||||||||||||||||||||||||||||||
15.5% | ||||||||||||||||||||||||||||||||||||||
160 | ||||||||||||||||||||||||||||||||||||||
10.4% | ||||||||||||||||||||||||||||||||||||||
140 | 8.2% | |||||||||||||||||||||||||||||||||||||
14.6% | ||||||||||||||||||||||||||||||||||||||
120 | ||||||||||||||||||||||||||||||||||||||
10.1% | 11.2% | |||||||||||||||||||||||||||||||||||||
100 | ||||||||||||||||||||||||||||||||||||||
21.4% | ||||||||||||||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||||||||||||||
17.5% | 9.4% | |||||||||||||||||||||||||||||||||||||
60 | 16.4% | |||||||||||||||||||||||||||||||||||||
19.4% | ||||||||||||||||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||||||||||||||
20 | ||||||||||||||||||||||||||||||||||||||
44.8 | 53.5 | 62.3 | 73.3 | 80.2 | 97.3 | 107.1 | 119.1 | 136.5 | 147.6 | 162.9 | 188.2 | |||||||||||||||||||||||||||
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
3 Nexus AG / Annual Report 2021 - Letter to our Shareholders
Our new "NEXUS / ADVANCED REPORTING" diagnostics solution, which supports the creation of findings and diagnoses based on image analyses, predefined terminologies and experience knowledge (AI), was at the heart of our development in 2021. The advantage: Findings can be produced significantly faster and in higher quality. We have also developed our "NEXUS / VNA," further, i.e., hospital-wide image and document archiving, which enables a complete view of patient records. The same applies to the new development "NEXUS / PORTAL", which facilitates communication between patients, referring physicians and hospitals.
Our ONE / NEXUS developments are all designed under the Total Experience approach, i.e., we want to create new spaces of experience for employees and patients through technologies and thus create personal experiences and enthusiasm. The success of our ONE / NEXUS product offensive proves us right. For this reason, we again invested approx. 19% of our sales or around EUR 35 million in new developments in 2021. This is a high value that is unique in our industry. Our strong position and good market prospects continue to justify these investments.
__ 2021: Further market consolidations
The good market prospects have also motivated other providers to push market consolidation forward in 2021. Private equity companies and strategic investors have concluded a larger number of small and medium- sized acquisitions in Germany and other European countries. Oracle Corporation (USA) announced the largest acquisition in 2021 with the acquisition of the healthcare-IT company Cerner Corporation (USA) at a total cost of USD 28.3 billion.
In 2021, we also strengthened our technological and human resources further by acquiring six small, highly specialized teams. We are currently focusing on companies with special know-how, with which we can jointly tap new market potential and provide synergies in the face of technological and sales challenges. Since February 2021, we have held a 51% interest in ITR Software GmbH Lindenberg im Allgäu. Thanks to its staff and the integration of its software products, we can serve the rehabilitation market even more thoroughly and expand our position. At the beginning of April 2021, we also acquired a majority stake in ANT- Informatik AG, Zurich (Switzerland). This further expanded our commitment to this area of CRM for hospitals and donor organizations. In June 2021, we acquired the company DC-SystemeInformatik GmbH, Heiligenhaus. The company specializes in the development and distribution of pathology and cytology systems. NEXUS is already the market leader in this area, and we are significantly strengthening our joint market position through this merger. Together, we are able to significantly accelerate the development of "digital pathology" and thus invest in a growth driver of the coming years.
In Switzerland, we have acquired a majority of two small companies with osoTec GmbH, Affoltern am Albis (Switzerland), and SINAPSI Sagl, Lugano (Switzerland). The aim is to strengthen our market position in the respective region and through product extensions. The asset deal in the Netherlands, which we implemented together of with the Dedalus Group, also includes a team that focuses on the development of drug and pharmacy software. We will work intensively on the integration of the new partner companies and software in the coming months. Here it is important to adapt and position the products of the companies as ONE / NEXUS products.
__ 2021: High Number of Incoming Orders
We were completely focused on the public funding programs in 2021. We have supported our customers in the conception and application process and helped them to meet the tight deadlines of the programs. Incoming orders from public funding programs did not play a major role this year.
Despite this strong focus on future order opportunities, we were also able to record very high incoming orders in 2021, win many tenders and implement projects. Here are a few examples: In Germany, we were commissioned by a large hospital group with the implementation of the digital medical records in almost 100 hospitals. The University Hospital Aachen has commissioned us with the digitization of its pathology area, the University Hospital Rostock with the digitization of all special diagnostics and the University Hospital Bonn has decided to introduce NEXUS / RIS and NEXUS / PATHOLOGY. In Switzerland, we will introduce our NEXUS / HISNG in the Paraplegic Center Nottwil, we were able to win a tender for an HIS introduction in 30 hospitals in the Wielkopolska region in Poland, and we were able to win a major HIS project in the Gelderse Vallei Hospital in the Netherlands.
__ Ralf Heilig, Chief Sales Officer (CSO)
Lower Austria has opted for our NEXUS / CURATOR solution in quality management in 77 healthcare facilities and in France we were able to win an important CSSD contract at the Centre Hospitalier Mulhouse. In Barcelona (Spain), Hospital Clinic opted for our obstetric solution NEXUS / ASTRAIA. We were able to enthuse Heiligenfeld Kliniken for our NEXUS / REHAB solution, and the hospital in Villingen-Schwenningen ordered the NEXUS / PATHOLOGY solution. Vivantes has introduced the NEXUS / CURATOR solution in all hospitals in Berlin and the Suhl Community Laboratory has introduced our NEXUS / SWISSLAB laboratory solution.
These order examples demonstrate that the market trusts our products and our company. NEXUS is regarded as an innovative and reliable partner that can also be relied on for long-term investment decisions. This is an important argument, because many customers are uncertain about the takeover of their software providers and are looking for secure alternatives.
Letter to our Shareholders - Nexus AG / Annual Report 2021 | 4 |
Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nexus AG published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2022 08:00:07 UTC.
